Ion-682884
Web15 apr. 2024 · This study aims to determine whether subcutaneous injection of an antisense oligonucleotide drug, known as ION-682884, that has been specifically designed to … Web1 jul. 2024 · AKCEA-TTR-L RX (ION-682884) is an antisense oligonucleotide (ASO) that inhibits the production of TTR. It has a similar design and sequence as inotersen (the parent compound), but is conjugated to a triantennary N-acetyl galactosamine (GalNAc3) moiety for selective receptor-mediated delivery to hepatocytes, the principal source of systemically …
Ion-682884
Did you know?
WebThe European Union Clinical Trials Register allows you to search for protocol and results information on: interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA); clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development. Web12 jul. 2024 · Satisfactory completion of Treatment Period and the End of Treatment Visit of the Index Study (ION-682884-CS2) OR diagnosis of ATTR-CM and satisfactory …
WebAdditional Study Information: The purpose of this study is to evaluate the efficacy and safety of ION-682884 given for 24 months in patients with hereditary transthyretin-mediated … WebNational Center for Biotechnology Information
Web13 apr. 2024 · Because ION-682884 is an antisense oligonucleotide similar to inotersen and because inotersen has been associated with thrombocytopenia and worsening renal …
Web26 nov. 2024 · Akcea Therapeutics and Ionis Pharmaceuticals announced the launch of a Phase 3 clinical trial evaluating the safety and efficacy of AKCEA-TTR-L Rx (ION-682884) for the treatment of adults with familial amyloid polyneuropathy (FAP). The global, open-label, randomized NEURO-TTRansform trial ( NCT04136184) is expected to start in …
WebION-682884 FREE ACID: Source: Code English Classification Tree Code System Code; FDA ORPHAN DRUG 827521. Created by admin on Sun Dec 18 15:05:52 UTC 2024, … read chapter 1052Web16 dec. 2024 · Eplontersen (ION-682884), a ligand-conjugated antisense oligonucleotide designed to degrade hepatic TTR mRNA, is being evaluated for the treatment of ATTRv amyloidosis with polyneuropathy (ATTRv-PN) in the phase 3, international, multicenter, open-label NEURO-TTRansform study (NCT04136184). how to stop my beard from growingWeb26 feb. 2024 · AKCEA-TTR-L Rx (ION-682884) is a ligand-conjugated antisense (LICA) drug designed for preferential delivery to hepatocytes, the primary source of systemically … how to stop my binge eating disorderWeb7 dec. 2024 · AKCEA-TTR-L Rx (ION-682884) is a ligand-conjugated antisense drug designed for receptor-mediated uptake by hepatocytes, the primary source of circulating transthyretin (TTR). Enhanced delivery of the antisense pharmacophore is expected to increase drug potency and support lower, less frequent dosing in treatment. Methods … read chapter 1053 one pieceWebAims: Amyloidogenic transthyretin (ATTR) amyloidosis is a fatal disease characterized by progressive cardiomyopathy and/or polyneuropathy. AKCEA-TTR-L Rx (ION-682884) is a ligand-conjugated antisense drug designed for receptor-mediated uptake by hepatocytes, the primary source of circulating transthyretin (TTR). Enhanced delivery of the antisense … how to stop my bed from slidingWebION-682884-CS13 ION-682884 (eplonterseno) PHARMACEUTICAL RESEARCH ASSOCIATES LTDA EudraCT: 2024-001427-40 AG348-C-020 AG-348(Mitapivate) PPD DO BRASIL SUPORTE A PESQUISA CLINICA LTDA NCT05031780 Foram liberados por decurso de prazo 4 ensaios clínicos, conforme previsto no Art.36 da RDC 09/2015. … how to stop my browser from being managedWebION-682884 FREE ACID: Source: Code English Classification Tree Code System Code; FDA ORPHAN DRUG 827521. Created by admin on Sun Dec 18 15:05:52 UTC 2024, Edited by admin on Sun Dec 18 15:05:52 UTC 2024. Code System Code Type Description; CAS: Source: 1637600-16-8. Created by admin ... how to stop my bones from hurting